Quinn Opportunity Partners LLC Invests $6.28 Million in uniQure N.V. $QURE

Quinn Opportunity Partners LLC purchased a new position in shares of uniQure N.V. (NASDAQ:QURE) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 107,600 shares of the biotechnology company’s stock, valued at approximately $6,281,000.

Several other large investors have also recently added to or reduced their stakes in QURE. Woodline Partners LP lifted its position in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of uniQure during the second quarter worth $215,000. SG Americas Securities LLC purchased a new stake in shares of uniQure during the second quarter worth $1,321,000. Main Management ETF Advisors LLC grew its stake in uniQure by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock valued at $786,000 after purchasing an additional 912 shares in the last quarter. Finally, Swiss National Bank purchased a new position in uniQure in the second quarter valued at about $1,080,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Down 8.3%

QURE stock opened at $15.53 on Friday. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a market cap of $971.09 million, a PE ratio of -4.50 and a beta of 0.73. The business’s 50-day simple moving average is $21.37 and its 200 day simple moving average is $29.49.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

Insider Buying and Selling at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 81,399 shares of company stock valued at $1,527,645 in the last quarter. 4.79% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus set a $14.00 price target on uniQure in a report on Monday, March 2nd. Leerink Partners reiterated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Tuesday. Finally, Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.